Transforming Growth Factor β: Tumor Suppressor or Promoter? Are Host Immune Cells the Answer?
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Therapies targeting transforming growth factor β (TGFβ) signaling using neutralizing antibodies and small molecular inhibitors are in multiple clinical trails. However, TGFβ is known to work as both a tumor suppressor and a tumor promoter, and current knowledge does not provide sufficient information on what factors mediate this switch in function and when this switch occurs. Recent advances in multiple disciplines suggest that immune cells from the tumor host may provide the answer. [Cancer Res 2008;68(22):9107–11]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It acts as a tumor suppressor in the initial stages of malignancies by suppressing cell proliferation and inducing apoptosis [159].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [159]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“lular carcinoma (34) and colorectal tumors predicting clinical outcome (35).”
Stromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,302 · cited 1×
“and hepatocyte growth factor–mediated signaling networks (25).”
Self-citationIL-21 initiates an alternative pathway to induce proinflammatory TH17 cells
Korn, T., Bettelli, E., Gao, W., Awasthi, A., Jäger, A., Strom, T. B., Oukka, M., & Kuchroo, V. K. (2007) · Nature · doi:10.1038/nature05970 · Cited by 1,848 · cited 1×
“TGFh, coordinated with IL-21, induces CD4CD25 regulatory T cells, which counterbalance the effect of IL-6 that promotes proinflammatory IL-17–producing T cells (14).”
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1926 · Cited by 1,267 · cited 4×
“However, TGFh can function both as a tumor suppressor and as a tumor promoter, which is extensively reviewed by Bierie and Moses (1).”
InfluentialSelf-citationMovahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., & Van Ginderachter, J. A. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,234 · cited 1×
“responses, but through distinct effector molecules and signaling pathways (19).”
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,174
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140 · cited 1×
“In addition to the immunosuppressive effect on tumor host, Gr-1CD11b cells also infiltrate into tumors and promote tumor angiogenesis and metastasis by producing high levels of matrix metalloproteinases (MMP) and TGFh (17, 27).”
Hiratsuka, S., Watanabe, A., Aburatani, H., & Maru, Y. (2006) · Nature Cell Biology · doi:10.1038/ncb1507 · Cited by 1,015 · cited 1×
“In the distant premetastatic lung, TGFh is one of the factors produced by tumor cells responsible for the production of the chemoattractants S100A8 and S100A9, which attract Mac1 myeloid cells (26).”
TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4
Padua, D., Zhang, X. H.-F., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., & Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.01.046 · Cited by 952
Ghiringhelli, F., Ménard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B., Vivier, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 949
Cited by
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974
The metastatic niche: adapting the foreign soil
Psaila, B., & Lyden, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2621 · Cited by 1,300
TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
Yang, L., Pang, Y., & Moses, H. L. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.04.002 · Cited by 1,023
Self-citationInitial steps of metastasis: Cell invasion and endothelial transmigration
van Zijl, F., Krupitza, G., & Mikulits, W. (2011) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2011.05.002 · Cited by 883
TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Dewidar, B., Meyer, C., Dooley, S., & Meindl-Beinker, A. N. (2019) · Cells · doi:10.3390/cells8111419 · Cited by 837
“Non-canonical pathways provide one explanation for the versatile effects of TGF-β signaling and its dichotomal functions, as for example described in carcinogenesis [36].”
Background
Metadata
- Authors
- Yang, L., & Moses, H. L.
- Affiliations
- Department of Cancer Biology, the Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tenessee
- Vanderbilt University (US)
- ORCID
- Moses, Harold L.
- Venue
- Cancer Research
- Published
- 2008-11-14
- Volume
- 68
- Issue
- 22
- Pages
- 9107-9111
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC2741321
- OpenAlex
- W1996348230
- Cited by
- 151
- References
- 35
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 3 · 2023: 11 · 2022: 10 · 2021: 7 · 2020: 6 · 2019: 4 · 2018: 4 · 2017: 7 · 2016: 7 · 2015: 4 · 2014: 10 · 2013: 11 · 2012: 15
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA085492, R01CA102162, U54CA126505)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- TGF-beta, TGF-beta signaling, tumor suppressor, tumor promoters, tumor microenvironment, host immune cells, TGF-β inhibitors, neutralizing antibodies, cancer immunotherapy
- MeSH terms
- Animals, Carcinogens, Humans, Immune System, Inflammation, Signal Transduction, Transforming Growth Factor beta, Receptors, Chemokine, Myeloid Cells, Tumor Suppressor Proteins, CD11b Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Transforming Growth Factor β: Tumor Suppressor or Promoter? Are Host Immune Cells the Answer? https://app.cochat.ai/papers/10.1158/0008-5472.can-08-2556
- The paper
- Yang, L., & Moses, H. L. (2008). Transforming Growth Factor β: Tumor Suppressor or Promoter? Are Host Immune Cells the Answer? Cancer Research. https://doi.org/10.1158/0008-5472.can-08-2556
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.